Axcelis Stock: $161 Target vs $91 Model as Shares Slip
Axcelis Technologies has beaten Wall Street earnings estimates in each of the last four reported quarters, yet shares continue to trade at $118.61 — roughly $42 below the analyst consensus target of $
Axcelis Stock: $161 Target vs $91 Model as Shares Slip
NEW YORK, October 14 —
A $70 spread between Wall Street's $161 consensus price target and GuruFocus's $90.94 intrinsic value estimate has turned Axcelis Technologies, Inc. (ACLS) into a live test of which valuation framework better prices a semiconductor equipment cycle. The shares, at $118.61, sit almost exactly between the two poles, and four consecutive earnings beats do nothing to close the gap between them.
- TTM revenue $0.87B, up 10.6%; gross margin 43.0%; trailing free cash flow $42M.
- Forward P/E 22.5x; $0.40B cash vs. $0.07B debt; market cap $3.66B.
- Short interest 6.7% of float; insider ownership approximately 0.7% of shares outstanding.
Beating Estimates, Losing Ground
Axcelis Technologies makes ion implantation systems, machines used to alter the electrical properties of silicon wafers at chipmakers' fabrication facilities, and supplements equipment sales with spare parts, upgrades, and maintenance contracts providing a recurring revenue layer. Four consecutive quarterly earnings beats, ranging from 1.4% to 33.1% positive surprises, speak to a business executing ahead of its own guidance trajectory. Yet shares have slid from the $145.01 level where insiders' tax-withholding transactions cleared in July to $118.61 today. Consistent beats that do not translate to price appreciation suggest the market is pricing something the quarterly cadence does not resolve.
The Multiple Is the Argument
The $161 analyst consensus implies 36% upside and presumably prices in Axcelis's four-quarter beat record alongside its 22.5x forward P/E on $2.98 trailing EPS. GuruFocus's GF Value model reaches a different conclusion: $90.94 intrinsic value versus a then-current price of $127.63, characterizing the stock as overvalued even after a 5.3% prior decline. The two frameworks are not arguing about earnings quality but about the multiple an equipment supplier deserves at this point in a capital-expenditure-sensitive fab investment cycle. A DCF calculator illustrates how small changes in assumed growth rates and discount rates reconcile or widen that gap.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| ACLS | $3.7B | 22.5x | +49.1% |
| COHU | $2.8B | 31.5x | +176.7% |
| KLIC | $4.4B | 14.3x | +121.0% |
| ENTG | $23.3B | 30.3x | +70.3% |
| PLAB | $1.7B | 13.7x | +23.9% |
| LSCC | $16.3B | 35.8x | +69.8% |
What the Next Checkpoint Must Settle
The balance sheet offers little to arbitrate the disagreement: $0.40B cash against $0.07B in debt is a genuine cushion, but trailing free cash flow of $42M against a $3.66B market cap leaves the stock priced largely on forward expectations rather than current cash generation. The quarterly earnings disclosure filed as an 8-K in August showed the recent trajectory; the next release will either extend the beat record or fracture it. A CFO seat that Form 4 filings dated July 15 still labeled "Interim" adds a governance layer to watch. Run the free Axcelis Technologies, Inc. deep-dive → to track how incoming data shifts this balance.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Axcelis Technologies has beaten Wall Street earnings estimates in each of the last four reported quarters, yet shares continue to trade at $118.61 — roughly $42 below the analyst consensus target of $161. A new wrinkle: a quantitative valuation model from GuruFocus places intrinsic value at $90.94, a figure that, if accurate, implies the stock remains overvalued even after its extended decline from mid-year highs.